Cardiovascular
Supraventricular Tachycardia
9
Pipeline Programs↗
1
Active Trials↗
3
Companies Involved↗
Supraventricular tachycardia is an early-stage landscape with 9 programs across 3 companies. The most active players are Advanz Pharma, Astellas, Val Adams. 1 therapy is approved with 3 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical5
Phase 1
No programs
Phase 2
No programs
Approved1
Analysis
Trial Status
6
clinical trials
Completed3 · 50%
Unknown status2 · 33%
Recruiting1 · 17%
Clinical Trials
Trial Activity
6 trials
Prospective Randomized Clinical Trial of Fetal Atrial Flutter & Supraventricular Tachycardia Therapy (FAST RCT)
Completed·—·Phase 3·NCT02624765·105 enrolled
Adenosine Versus Verapamil for Management of Supraventricular Tachycardia Post- Coronary Artery Bypass Grafting
Completed·—·N/A·NCT04203368·268 enrolled
Management of Supraventricular Tachycardia of Children
Unknown status·—·N/A·NCT03528616·50 enrolled
Treatment of Supraventricular Tachycardia in Patients With Non-cardiac Surgery by Dexmedetomidine
Unknown status·—·N/A·NCT04284150·60 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)